Evidence map›Paper›PMID 36387168›Full record

ArticleFrontiers in oncology2022

Comprehensive characterization of RNA cargo of extracellular vesicles in breast cancer patients undergoing neoadjuvant chemotherapy.

Lilite Sadovska, Pawel Zayakin, Kristaps Eglītis, Edgars Endzeliņš, Ilze Radoviča-Spalviņa, Elīza Avotiņa, Jānis Auders, Laura Keiša, Inta Liepniece-Karele, Mārcis Leja and 2 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lilite SadovskaCancer Biomarker group, Latvian Biomedical Research and Study Centre, Riga, Latvia.
Pawel ZayakinCancer Biomarker group, Latvian Biomedical Research and Study Centre, Riga, Latvia.
Kristaps EglītisLatvian Oncology Center, Riga Eastern Clinical University Hospital, Riga, Latvia.
Edgars EndzeliņšCancer Biomarker group, Latvian Biomedical Research and Study Centre, Riga, Latvia.
Ilze Radoviča-SpalviņaGenera Ltd., Riga, Latvia.
Elīza AvotiņaInstitute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia.
Jānis AudersCancer Biomarker group, Latvian Biomedical Research and Study Centre, Riga, Latvia.
Laura KeišaCancer Biomarker group, Latvian Biomedical Research and Study Centre, Riga, Latvia.
Inta Liepniece-KareleLatvian Oncology Center, Riga Eastern Clinical University Hospital, Riga, Latvia.
Mārcis LejaInstitute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia.
Jānis EglītisLatvian Oncology Center, Riga Eastern Clinical University Hospital, Riga, Latvia.
Aija LinēCancer Biomarker group, Latvian Biomedical Research and Study Centre, Riga, Latvia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) are g7aining increased attention as carriers of cancer-derived molecules for liquid biopsies. Here, we studied the dynamics of EV levels in the plasma of breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NAC) and explored the relevance of their RNA cargo for the prediction of patients' response to the therapy. EVs were isolated from serial blood samples collected at the time of diagnosis, at the end of NAC, and 7 days, 6, and 12 months after the surgery from 32 patients with locally advanced BC, and 30 cancer-free healthy controls (HCs) and quantified by nanoparticle tracking analysis. The pre-treatment levels of EVs in BC patients were higher than in HCs, significantly increased during the NAC and surgery, and decreased to the levels found in HCs 6 months after surgery, thus showing that a substantial fraction of plasma EVs in BC patients are produced due to the disease processes and treatment. RNA sequencing analysis revealed that the changes in the EV levels were associated with the alterations in the proportions of various RNA biotypes in EVs. To search for RNA biomarkers that predict response to the NAC, patients were dichotomized as responders and non-responders based on Miller-Payne grades and differential expression analyses were carried out between responders and non-responders, and HCs. This resulted in the identification of 6 miRNAs, 4 lncRNAs, and 1 snoRNA that had significantly higher levels in EVs from non-responders than responders at the time of diagnosis and throughout the NAC, and significantly lower levels in HCs, thus representing biomarkers for the prediction of response to NAC at the time of diagnosis. In addition, we found 14 RNAs representing piRNA, miRNA, lncRNA, snoRNA, and snRNA biotypes that were induced by NAC in non-responders and 2 snoRNAs and 1 piRNA that were induced by NAC in patients with early disease progression, thus warranting further functional studies on their role in chemoresistance and metastasis.

Indexed as

breast cancerextracellular vesiclesliquid biopsyneoadjuvant chemotherapyprognostic biomarkerRNA biotypesRNA sequencingsnoRNA

Identifiers

PMID36387168
PMCPMC9644097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.